Skip to main content
ZEVRA THERAPEUTICS, INC. logo

ZEVRA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ZVRA ISIN · US4884452065 LEI · 254900CU6T74V18Y1W18 US Manufacturing
Filings indexed 830 across all filing types
Latest filing 2020-02-08 Director's Dealing
Country US United States of America
Listing US ZVRA

About ZEVRA THERAPEUTICS, INC.

https://zevra.com/

Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for patients with rare diseases. The company focuses on addressing significant unmet medical needs by combining a data-driven scientific approach with a patient-first perspective. Its portfolio includes commercial products such as MIPLYFFA®, an FDA-approved treatment for Niemann-Pick disease type C (NPC), and OLPRUVA®. Zevra Therapeutics also maintains a late-stage clinical pipeline, specializing in advancing promising medicines that face complex clinical and regulatory challenges for conditions with limited or no available treatments.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2020-02-08 English
FORM 4
Director's Dealing
2020-02-08 English
FORM 4
Director's Dealing
2020-02-08 English
Regulatory Filings 2020
Regulatory Filings
2020-02-05 English
FORM 8-K
Delisting Announcement Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on the company's notice of delisting or transfer of listing from The Nasdaq Global Market to The Nasdaq Capital Market, compliance issues with Nasdaq listing requirements, and related forward-looking statements. There are no financial statements or detailed financial data presented, but rather regulatory and compliance information about the listing status. This matches the definition of a Delisting Announcement (DLST). The document length is 9264 characters, which is sufficient to contain substantive information rather than a mere announcement of a report. Therefore, the appropriate classification is DLST with high confidence.
2020-01-16 English
Regulatory Filings 2020
Regulatory Filings
2020-01-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.